Details of the Drug

General Information of Drug (ID: DM7HXWT)

Drug Name
Nilotinib
Synonyms
NIL; Nilotinibum; Tasigna (Novartis); Nilotinib (INN/USAN); Nilotinib, AMN107, Tasigna; Tasigna, AMN-107, Nilotinib; L-1-yl)-3-(trifluoromethyl)phenyl]benzamide; Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-(9CI); 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazo; 4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; Nilotinib (BCR-ABL inhibitor 2nd gen)
Indication
Disease Entry ICD 11 Status REF
Chronic myelogenous leukaemia 2A20.0 Approved [1], [2]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 529.5
Topological Polar Surface Area (xlogp) 4.9
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 9
ADMET Property
Absorption
The drug is orally available [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Elimination
4% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 15 hours [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 21.58252 micromolar/kg/day [6]
Chemical Identifiers
Formula
C28H22F3N7O
IUPAC Name
4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide
Canonical SMILES
CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
InChI
InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)
InChIKey
HHZIURLSWUIHRB-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
644241
ChEBI ID
CHEBI:52172
CAS Number
641571-10-0
DrugBank ID
DB04868
TTD ID
D00STL
VARIDT ID
DR00013
INTEDE ID
DR1155
ACDINA ID
D00468

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fusion protein Bcr-Abl (Bcr-Abl) TTS7G69 BCR_HUMAN-ABL1_HUMAN Modulator [2]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [7]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [7]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [8]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [8]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Nilotinib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Nilotinib caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [75]
Ruxolitinib DM7Q98D Minor Decreased metabolism of Nilotinib caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [76]
Coadministration of a Drug Treating the Disease Different from Nilotinib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Nilotinib and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [77]
Sarecycline DMLZNIQ Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Sarecycline . Acne vulgaris [ED80] [75]
Metreleptin DM1NOEK Moderate Increased metabolism of Nilotinib caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [75]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Nilotinib and Ivosidenib. Acute myeloid leukaemia [2A60] [78]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Nilotinib and Midostaurin. Acute myeloid leukaemia [2A60] [78]
Arn-509 DMT81LZ Major Increased metabolism of Nilotinib caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [75]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Nilotinib and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [78]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Nilotinib and Levalbuterol. Asthma [CA23] [79]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Nilotinib and Retigabine. Behcet disease [4A62] [78]
Cariprazine DMJYDVK Moderate Decreased metabolism of Nilotinib caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [80]
Erdafitinib DMI782S Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [81]
Pexidartinib DMS2J0Z Major Decreased metabolism of Nilotinib caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [82]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Nilotinib and Eribulin. Breast cancer [2C60-2C6Y] [78]
Talazoparib DM1KS78 Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [83]
LY2835219 DM93VBZ Moderate Decreased metabolism of Nilotinib caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [84]
Tucatinib DMBESUA Major Decreased metabolism of Nilotinib caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [77]
Palbociclib DMD7L94 Moderate Decreased metabolism of Nilotinib caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [75]
Alpelisib DMEXMYK Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Alpelisib. Breast cancer [2C60-2C6Y] [75]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Nilotinib caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [85]
Bosutinib DMTI8YE Moderate Decreased metabolism of Nilotinib caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [75]
Macitentan DMP79A1 Moderate Decreased metabolism of Nilotinib caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [86]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Nilotinib and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [78]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Nilotinib and Olodaterol. Chronic obstructive pulmonary disease [CA22] [87]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Nilotinib and Vilanterol. Chronic obstructive pulmonary disease [CA22] [79]
Fidaxomicin DMFP6MV Minor Decreased clearance of Nilotinib due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [77]
Intedanib DMSTA36 Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Intedanib. Colorectal cancer [2B91] [88]
Ulipristal DMBNI20 Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Ulipristal. Contraceptive management [QA21] [75]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Nilotinib and Pasireotide. Cushing syndrome [5A70] [78]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Nilotinib and Osilodrostat. Cushing syndrome [5A70] [78]
Lumacaftor DMCLWDJ Major Increased metabolism of Nilotinib caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [89]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Nilotinib caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [75]
MK-8228 DMOB58Q Moderate Decreased metabolism of Nilotinib caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [75]
Rivaroxaban DMQMBZ1 Moderate Decreased metabolism of Nilotinib caused by Rivaroxaban mediated inhibition of CYP450 enzyme. Deep vein thrombosis [BD71] [90]
Desvenlafaxine DMHD4PE Moderate Decreased metabolism of Nilotinib caused by Desvenlafaxine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [75]
OPC-34712 DMHG57U Major Decreased metabolism of Nilotinib caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [91]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Nilotinib caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [92]
SODIUM CITRATE DMHPD2Y Moderate Decreased absorption of Nilotinib due to altered gastric pH caused by SODIUM CITRATE. Discovery agent [N.A.] [77]
Ospemifene DMC4GEI Moderate Decreased metabolism of Nilotinib caused by Ospemifene mediated inhibition of CYP450 enzyme. Dyspareunia [GA12] [93]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Nilotinib and Deutetrabenazine. Dystonic disorder [8A02] [78]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Nilotinib and Ingrezza. Dystonic disorder [8A02] [78]
Cenobamate DMGOVHA Moderate Increased metabolism of Nilotinib caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [75]
Rufinamide DMWE60C Moderate Increased metabolism of Nilotinib caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [75]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Nilotinib caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [75]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Nilotinib and Cannabidiol. Epileptic encephalopathy [8A62] [76]
Bay 80-6946 DMLOS5R Moderate Decreased metabolism of Nilotinib caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [94]
Tazemetostat DMWP1BH Moderate Increased metabolism of Nilotinib caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [75]
Mirabegron DMS1GYT Minor Decreased metabolism of Nilotinib caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [95]
Dexlansoprazole DM1DBV5 Moderate Increased risk of hypomagnesemia by the combination of Nilotinib and Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [75]
Ripretinib DM958QB Moderate Decreased metabolism of Nilotinib caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [77]
Avapritinib DMK2GZX Moderate Decreased metabolism of Nilotinib caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [76]
Boceprevir DMBSHMF Major Decreased metabolism of Nilotinib caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [75]
Telaprevir DMMRV29 Major Decreased metabolism of Nilotinib caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [77]
Daclatasvir DMSFK9V Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Daclatasvir. Hepatitis virus infection [1E50-1E51] [75]
GS-5885 DMSL3DX Moderate Decreased clearance of Nilotinib due to the transporter inhibition by GS-5885. Hepatitis virus infection [1E50-1E51] [96]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Nilotinib and Brentuximab vedotin. Hodgkin lymphoma [2B30] [97]
MK-1439 DM215WE Minor Decreased metabolism of Nilotinib caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [98]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Nilotinib and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [78]
Cobicistat DM6L4H2 Major Decreased metabolism of Nilotinib caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [77]
Dolutegravir DMCZGRE Minor Decreased metabolism of Nilotinib caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [99]
Etravirine DMGV8QU Moderate Decreased metabolism of Nilotinib caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [100]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Nilotinib and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [78]
Raltegravir DMYURI6 Minor Decreased metabolism of Nilotinib caused by Raltegravir mediated inhibition of UGT. Human immunodeficiency virus disease [1C60-1C62] [101]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Nilotinib and Mipomersen. Hyper-lipoproteinaemia [5C80] [102]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Nilotinib and Teriflunomide. Hyper-lipoproteinaemia [5C80] [103]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Nilotinib and BMS-201038. Hyper-lipoproteinaemia [5C80] [104]
Sodium zirconium cyclosilicate DMCSLZ4 Moderate Decreased absorption of Nilotinib due to altered gastric pH caused by Sodium zirconium cyclosilicate. Hyperkalaemia [5C76] [76]
Aliskiren DM1BV7W Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [78]
Levamlodipine DM92S6N Moderate Decreased metabolism of Nilotinib caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [75]
Tolvaptan DMIWFRL Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [105]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Nilotinib caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [75]
Suvorexant DM0E6S3 Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Suvorexant. Insomnia [7A00-7A0Z] [75]
ITI-007 DMUQ1DO Moderate Decreased metabolism of Nilotinib caused by ITI-007 mediated inhibition of UGT. Insomnia [7A00-7A0Z] [106]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Nilotinib and Polyethylene glycol. Irritable bowel syndrome [DD91] [107]
Naloxegol DML0B41 Minor Decreased metabolism of Nilotinib caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [108]
Pemigatinib DM819JF Moderate Decreased metabolism of Nilotinib caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [76]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Nilotinib and Denosumab. Low bone mass disorder [FB83] [109]
Brigatinib DM7W94S Moderate Decreased metabolism of Nilotinib caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [77]
PF-06463922 DMKM7EW Moderate Increased metabolism of Nilotinib caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [75]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Nilotinib and Osimertinib. Lung cancer [2C25] [78]
Capmatinib DMYCXKL Moderate Decreased metabolism of Nilotinib caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [75]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Nilotinib and Lumefantrine. Malaria [1F40-1F45] [77]
Artesunate DMR27C8 Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Artesunate. Malaria [1F40-1F45] [75]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Nilotinib and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [78]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Nilotinib and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [110]
Idelalisib DM602WT Major Decreased metabolism of Nilotinib caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [77]
GDC-0199 DMH0QKA Major Decreased metabolism of Nilotinib caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [77]
Acalabrutinib DM7GCVW Moderate Decreased metabolism of Nilotinib caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [111]
Ibrutinib DMHZCPO Moderate Decreased metabolism of Nilotinib caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [112]
Ponatinib DMYGJQO Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Ponatinib. Mature B-cell lymphoma [2A85] [75]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Nilotinib and Vemurafenib. Melanoma [2C30] [78]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Nilotinib and LGX818. Melanoma [2C30] [78]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Nilotinib caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [75]
Lasmiditan DMXLVDT Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Lasmiditan. Migraine [8A80] [113]
Flibanserin DM70DTN Moderate Decreased metabolism of Nilotinib caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [114]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Nilotinib and Tecfidera. Multiple sclerosis [8A40] [115]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Nilotinib and Siponimod. Multiple sclerosis [8A40] [77]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Nilotinib and Fingolimod. Multiple sclerosis [8A40] [116]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Nilotinib and Ocrelizumab. Multiple sclerosis [8A40] [117]
Ozanimod DMT6AM2 Major Increased risk of prolong QT interval by the combination of Nilotinib and Ozanimod. Multiple sclerosis [8A40] [78]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Nilotinib and Romidepsin. Mycosis fungoides [2B01] [78]
Rolapitant DM8XP26 Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [77]
S-297995 DM26IH8 Moderate Decreased metabolism of Nilotinib caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [76]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Nilotinib and Rucaparib. Ovarian cancer [2C73] [78]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Nilotinib and Triclabendazole. Parasitic worm infestation [1F90] [78]
Istradefylline DM20VSK Moderate Decreased metabolism of Nilotinib caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [75]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Nilotinib and Pimavanserin. Parkinsonism [8A00] [78]
Abametapir DM2RX0I Moderate Decreased metabolism of Nilotinib caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [118]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Nilotinib and Macimorelin. Pituitary gland disorder [5A60-5A61] [119]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Nilotinib and Lefamulin. Pneumonia [CA40] [120]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Nilotinib caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [77]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Nilotinib and Degarelix. Prostate cancer [2C82] [78]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Nilotinib and ABIRATERONE. Prostate cancer [2C82] [78]
Enzalutamide DMGL19D Major Increased metabolism of Nilotinib caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [75]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Nilotinib and Relugolix. Prostate cancer [2C82] [121]
Darolutamide DMV7YFT Minor Decreased metabolism of Nilotinib caused by Darolutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [122]
Silodosin DMJSBT6 Moderate Decreased metabolism of Nilotinib caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [123]
Selexipag DMAHSU0 Moderate Decreased metabolism of Nilotinib caused by Selexipag mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [124]
Ambrisentan DMD1QXW Moderate Decreased metabolism of Nilotinib caused by Ambrisentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [75]
Riociguat DMXBLMP Moderate Decreased metabolism of Nilotinib caused by Riociguat mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [77]
Axitinib DMGVH6N Moderate Decreased metabolism of Nilotinib caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [76]
Temsirolimus DMS104F Moderate Decreased metabolism of Nilotinib caused by Temsirolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [75]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Nilotinib and Canakinumab. Rheumatoid arthritis [FA20] [125]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Nilotinib and Rilonacept. Rheumatoid arthritis [FA20] [125]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Nilotinib and Golimumab. Rheumatoid arthritis [FA20] [126]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Nilotinib and Iloperidone. Schizophrenia [6A20] [78]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Nilotinib and Amisulpride. Schizophrenia [6A20] [78]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Nilotinib and Asenapine. Schizophrenia [6A20] [78]
LDE225 DMM9F25 Moderate Decreased metabolism of Nilotinib caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [127]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Nilotinib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [76]
Larotrectinib DM26CQR Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [77]
PDX-101 DM6OC53 Moderate Decreased metabolism of Nilotinib caused by PDX-101 mediated inhibition of UGT. Solid tumour/cancer [2A00-2F9Z] [128]
Trabectedin DMG3Y89 Moderate Decreased metabolism of Nilotinib caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [76]
Armodafinil DMGB035 Minor Decreased metabolism of Nilotinib caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [77]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Nilotinib and LEE011. Solid tumour/cancer [2A00-2F9Z] [78]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Nilotinib and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [78]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Nilotinib and Pitolisant. Somnolence [MG42] [78]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Nilotinib and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [78]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Nilotinib caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [129]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [75]
Apixaban DM89JLN Moderate Decreased metabolism of Nilotinib caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [76]
Brilinta DMBR01X Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Brilinta. Thrombosis [DB61-GB90] [75]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Nilotinib and Lenvatinib. Thyroid cancer [2D10] [78]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Nilotinib and Cabozantinib. Thyroid cancer [2D10] [78]
Elagolix DMB2C0E Moderate Increased metabolism of Nilotinib caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [75]
Betrixaban DM2C4RF Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Betrixaban. Venous thromboembolism [BD72] [75]
⏷ Show the Full List of 145 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferric oxide black E00522 16211978 Colorant
Gelatin E00630 Not Available Other agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Poloxamer 188 E00645 Not Available Emulsifying agent; Solubilizing agent; Surfactant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Colcothar yellow E00436 518696 Colorant
Haematite red E00236 14833 Colorant
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
⏷ Show the Full List of 13 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Nilotinib Hydrochloride Monohydrate eq 50mg base capsule eq 50mg base Capsule Oral
Nilotinib Hydrochloride Monohydrate eq 150mg base capsule eq 150mg base Capsule Oral
Nilotinib Hydrochloride Monohydrate eq 200mg base capsule eq 200mg base Capsule Oral
Nilotinib 150 mg capsule 150 mg Oral Capsule Oral
Nilotinib 200 mg capsule 200 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5697).
2 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 BDDCS applied to over 900 drugs
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64.
8 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
9 KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
10 Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87.
11 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
12 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
22 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
23 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
24 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
25 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
26 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
27 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
28 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
29 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
30 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
31 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
32 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
33 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
34 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
35 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
36 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
37 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
38 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
39 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
40 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
41 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
42 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
43 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
44 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
45 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
46 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
47 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
48 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
49 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
50 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
51 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
52 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
53 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
54 Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
55 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
56 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
57 The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
58 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
59 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
60 FDA Drug Development and Drug Interactions
61 LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
62 Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
63 Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
64 Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
65 Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
66 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
67 Danusertib, an aurora kinase inhibitor.Expert Opin Investig Drugs.2012 Mar;21(3):383-93.
68 ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia, NorthBuilding, 2014, 120-125.
69 Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 Dec 12;381(24):2315-2326.
70 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
71 Design, synthesis and preclinical evaluation of NRC-AN-019. Int J Oncol. 2013 Jan;42(1):168-78.
72 Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors. Cell Biosci. 2019 Oct 26;9:88.
73 NPB001-05 inhibits Bcr-Abl kinase leading to apoptosis of imatinib-resistant cells. Front Biosci (Elite Ed). 2011 Jun 1;3:1273-88.
74 Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood. 2002 Jan 15;99(2):664-71.
75 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
76 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
77 Cerner Multum, Inc. "Australian Product Information.".
78 Canadian Pharmacists Association.
79 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
80 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
81 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
82 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
83 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
84 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
85 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
86 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
87 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
88 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
89 Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
90 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
91 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
92 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
93 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
94 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
95 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
96 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
97 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
98 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
99 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
100 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
101 Product Information. Isentress (raltegravir). Merck & Company Inc, West Point, PA.
102 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
103 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
104 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
105 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
106 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
107 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
108 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
109 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
110 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
111 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
112 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
113 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
114 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
115 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
116 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
117 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
118 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
119 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
120 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
121 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
122 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
123 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
124 Product Information. Uptravi (selexipag). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
125 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
126 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
127 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
128 Product Information. Beleodaq (belinostat). Spectrum Pharmaceuticals Inc, Irvine, CA.
129 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.